Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody

被引：0

作者：

Li, Fu ^{[1
]}

Li, Jingrong ^{[1
]}

Yin, Ke ^{[1
]}

Zhang, Juan ^{[1
]}

Li, Zhenhu ^{[1
]}

Lu, Liang ^{[1
]}

Bao, Yuanwu ^{[1
]}

Pu, Dan ^{[1
]}

Qin, Zhen ^{[1
]}

Zheng, Yong ^{[2
]}

Yang, Baotian ^{[2
]}

Li, Jing ^{[2
]}

Wang, Xinzhong Jon ^{[1
]}

机构：

[1] CStone Pharmaceut Co Ltd, Shanghai, Peoples R China

[2] Wuxi Biol Co Ltd, Shanghai, Peoples R China

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.SABCS18-4121

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4121

引用

页数：2

共 50 条

[31] A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other Cancer
Xu, Xu
Yan, Shih-Long
Yo, Yi-Te
Chiang, Peiyu
Tsai, Chan-Yen
Lin, Lih-Ling
Qin, Albert
CANCERS, 2024, 16 (17)
[32] Preclinical PD-1 resistance models: Crucial tools for unveiling PD-1 resistance mechanisms and advancing novel treatment strategies
Zhu, Yini
Fang, Yuan
Wang, Huiyi
Xing, Jun
Yang, Lu
Zhao, Jing
Gao, Xiang
Ju, Cunxiang
CANCER RESEARCH, 2024, 84 (06)
[33] Comparative characterization of two monoclonal antibodies targeting canine PD-1
Kocikowski, Mikolaj
Dziubek, Katarzyna
Wegrzyn, Katarzyna
Hrabal, Vaclav
Zavadil-Kokas, Filip
Vojtesek, Borivoj
Alfaro, Javier Antonio
Hupp, Ted
Parys, Maciej
FRONTIERS IN IMMUNOLOGY, 2024, 15
[34] The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation
Zhang, Juan
Li, Zhenhu
Tang, Liang
Liu, Linlin
Ren, Zhaoxiang
Ma, Jingshu
Shi, Qingmei
Bao, Yuanwu
Lu, Liang
Zheng, Yong
Yang, Baotian
Li, Jing
Wang, Xinzhong Jon
CANCER RESEARCH, 2020, 80 (16)
[35] Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS']JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody
Fu, Jie
Wang, Fang
Dong, Li-Hou
Zhang, Jing
Deng, Cheng-lian
Wang, Xue-li
Xie, Xin-yao
Zhang, Jing
Deng, Ruo-xian
Zhang, Li-bo
Wu, Hai
Feng, Hui
Chen, Bo
Song, Hai-feng
ACTA PHARMACOLOGICA SINICA, 2017, 38 (05) : 710 - 718
[36] Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody
Laken, H.
Kehry, M.
McNeeley, P.
Neben, T.
Zhang, J.
Jenkins, D.
Wilcoxen, K.
EUROPEAN JOURNAL OF CANCER, 2016, 69 : S102 - S102
[37] In vitro and in vivo characterization of the PD-1 targeting antibody BI 754091
Zettl, Markus
Wurm, Melanie
Schaaf, Otmar
Tirapu, Inigo
Mostboeck, Sven
Reschke, Markus
Schmidbauer, Stephan-Michael
Frego, Lee
Lorenz, Ivo C.
Thibodeau, Michael
Blanset, Diann
Cifuentes, Elisa Oquendo
Moll, Jurgen
Kraut, Norbert
Borges, Eric
Vogt, Anne
Sedgwick, Jonathon
Waizenegger, Irene C.
CANCER RESEARCH, 2018, 78 (13)
[38] Novel cell-based bioassays for monoclonal antibody and bispecific molecules in PD-1 blockade monotherapy and combination therapy
Grailer, Jamison
Gilden, Julia
Wang, Jun
Garvin, Denise
Stecha, Pete
Hartnett, Jim
Edenson, Steven
Fan, Frank
Cong, Mei
Cheng, Zhi-jie Jey
CANCER RESEARCH, 2022, 82 (12)
[39] Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions
Maghrouni, Abolfazl
Givari, Maryam
Jalili-Nik, Mohammad
Mollazadeh, Hamid
Bibak, Bahram
Sadeghi, Mohammad Montazami
Afshari, Amir R.
Johnston, Thomas P.
Sahebkar, Amirhossein
INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 93
[40] PRECLINICAL STUDIES SUPPORT CLINICAL DEVELOPMENT OF AZD2936, A MONOVALENT BISPECIFIC HUMANIZED ANTIBODY TARGETING PD-1 AND TIGIT
Lee, Karin
Malhotra, Deepali
Pryts, Stacy
Clancy-Thompson, Eleanor
Omar, Bilal
Naiman, Brian
Overstreet, Michael
Taylor, Devon
Yang, Chunning
Mulgrew, Kathy
Xiao, Zhan
Wang, Yue
Moody, Gordon
Cobbold, Mark
Mazor, Yariv
Hammond, Scott
Pollizzi, Kristen
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A489 - A489

← 1 2 3 4 5 →